Valmark Advisers Inc. Grows Holdings in Danaher Co. (NYSE:DHR)

Valmark Advisers Inc. raised its position in shares of Danaher Co. (NYSE:DHR) by 11.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,900 shares of the conglomerate’s stock after purchasing an additional 302 shares during the period. Valmark Advisers Inc.’s holdings in Danaher were worth $806,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its stake in shares of Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC raised its holdings in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. boosted its stake in shares of Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the period. Trust Co of Kansas boosted its stake in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares during the period. Finally, Abacus Planning Group Inc. grew its position in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after purchasing an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.2 %

Shares of DHR opened at $242.32 on Thursday. The company’s fifty day simple moving average is $267.83 and its 200-day simple moving average is $260.42. The company has a market cap of $179.48 billion, a P/E ratio of 41.07, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $188.75 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DHR shares. Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. TD Cowen upped their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Finally, UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.